Yutaka Kohgo, Journal of Gastroenterology volume 39, pages1226–1227 (2004)

https://link.springer.com/article/10.1007%2Fs00535-004-1509-4

Hiroyuki Hanai ¹, Ken Takeuchi, Takayuki Iida, Nobuhito Kashiwagi, Abby R Saniabadi, Isao Matsushita, Yoshihiko Sato, Naoki Kasuga, Toshihiro Nakamura, Dig Dis Sci. 2004 Sep;49(9):1438-43.

In conclusion, GM appear to contribute to intestinal inflammation and UC activity and reduction of these cells by GMA should benefit patients with active UC. Further, the correlations among calprotectin, UC activities, and PB neutrophils should serve as the basis for preemptive actions to control this disease.

https://pubmed.ncbi.nlm.nih.gov/15481316/

Jorge Amil Dias, J Pediatr Gastroenterol Nutr. 2004 Nov;39(5):485-6.

https://pubmed.ncbi.nlm.nih.gov/15572886/

Hiroyuki Hanai ¹, Fumitoshi Watanabe, Masami Yamada, Yoshihiko Sato, Ken Takeuchi, Takayuki Iida, Kotaro Tozawa, Tatsuo Tanaka, Yasuhiko Maruyama, Isao Matsushita, Yasushi Iwaoka, Abby Saniabadi, Am J Gastroenterol. 2004 Aug;99(8):1532-8.

The sources of s-RI/RII are believed to be activated monocytes and neutrophils with further release when these leukocytes adhere to the column carriers. s-RI/RII released during GMA should contribute to the clinical efficacy of this procedure.

https://pubmed.ncbi.nlm.nih.gov/15307873/

Kanako Mori ¹, Takao Yoshihara, Takashi Ando, Satoko Tsubai, Satoshi Matsuo, Michiko Aoyama, Tohru Yamamoto, Yoshio Kawase, J Pediatr Gastroenterol Nutr. 2004 Nov;39(5):549-51

https://pubmed.ncbi.nlm.nih.gov/15572898/

Makoto Higuchi, AkihiroShinii ,NaoshiNakamura , IaijiAkamatsu, Hideo Arakura, Tbru Ichikawa , Kazuhiko Horab ,YejiKamijo ,Ybko Kanekoi, rfetuji Kakegawa and Kendo Kiyosawa, Jpn JApheresis23 (2):189-19S,2004

Fourpatients (3men and 1 woman) with intractable ulcerative colitis(UC)were treated using granulocytapheresis (GCAP) with Adacolumn. Mean age at the first GCAP was 37.5± 11years.Mean observation
period beforeGCAP was 157± 105 months. A clinical activity index (CAI,Rachmilewitzcriteria) and Matts’
endoscopic classification were used forthe estimation. GCAP was not effective intwo cases, however it,was
very effective inthe others. TheCAI score of one male patient decreased from8 to 5,and Matts’ grade from
3 to 2,after the 5thGCAR his patient could be taken off conicosteroid and the immunosuppressant.
Then he received GCAP every month. Both his CAI score and Matts’grade had decreased to 1sixteen months
after the first GCAR Four sessions of GCAP enabled us to reduce the prednisolone dose from20 to 5 mg lday,
and loweredt heCAI score (8to4) of another male patient before tota1 colectomy, Further examination is needed of the indications, times and intervals of GCAP in the treatment of intractable

https://dl.ndl.go.jp/view/download/digidepo_10555521_po_ART0003553409.pdf?contentNo=1&alternativeNo=

F Cuenca ¹, J García Paredes, J L Mendoza, D M Cruz, A Herrero, M Díaz-Rubio, Rev Esp Enferm Dig. 2004 Jul;96(7):501-3, 504-6.

Granulocyte apheresis is a safe and well tolerated therapeutic modality that can be a valid therapeutic alternative in the induction of remission in inflammatory bowel disease, although controlled clinical trials must be conducted to define long-term efficacy, as well as to establish “optimal patient” selection, re-treatment interval, and number of sessions.

https://pubmed.ncbi.nlm.nih.gov/15283632/

Kazuo Kusugami ¹, Kenji Ina, Takafumi Ando, Kenji Hibi, Yuji Nishio, Hidemi Goto, J Gastroenterol. 2004 Dec;39(12):1129-37.

Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms. Although decades of clinical experience in IBD management has led to optimized approaches for achieving the induction and maintenance of remission, the disease in some patients is still refractory to conventional medical treatment, or the effectiveness of these drugs can be limited by treatment-related side effects. Significant progress in our understanding of the pathogenesis of IBD has yielded several immunomodulatory approaches with novel biological agents or apparatus, such as cyclosporine, cytoprotective agents, infliximab, and leukocytapheresis. Further immunomodulatoy therapy, aiming at the inhibition of molecular and cellular mediators, is anticipated, in parallel with the clarification of immunoinflammatory pathways in IBD. An additional goal will be to identify factors predictive of response to treatment with each novel immunomodulatory agent or apparatus. This will help provide each patient with optimized and individualized therapy, thereby increasing therapeutic efficacy and reducing possible side effects.

https://pubmed.ncbi.nlm.nih.gov/15622475/

Toshihide Ohmori, Akio Yamagiwa, Itaru Nakamura, Kou Nishikawa, Abby R Saniabadi, Am J Gastroenterol. 2003 Sep;98(9):2101-2.

https://pubmed.ncbi.nlm.nih.gov/14499797/